If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJEFI.L Regulatory News (JEFI)

  • There is currently no data for JEFI

Update research from QuotedData

20 Jul 2021 11:01

RNS Number : 8319F
Jupiter Emerging & Frontier Inc.Tst
20 July 2021
 

Jupiter Emerging & Frontier Income - Update research from QuotedData

1st June 2021

 

Out in front

 

In both total net asset value (NAV) and share price return terms, Jupiter Emerging & Frontier Income (JEFI) has been the pacesetter within its peer group since the November 2020 vaccine announcements. Manager Ross Teverson and the team's long-held view that stocks were priced more attractively outside of China has been paying off, led by its Taiwan-based holdings in particular.

 

JEFI's bottom-up approach, which combines value and growth elements, has matched well with the shift away from growth stocks. A portfolio comprising predominantly of stocks with above-average dividend yields, the absence of reliance on China and India, and a mandate that allows investments into both emerging (EM) and frontier (FM) markets makes JEFI a unique proposition (see page 14). Despite its smaller size, it is trading at one of the tightest discounts within its peer group. A return to the pre-pandemic premium share price to NAV rating would allow JEFI to grow by raising capital and broaden its attraction to institutional investors.

 

Full research:

https://quoteddata.com/research/jupiter-emerging-frontier-income-front/

 

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note on Jupiter Emerging & Frontier Income Trust and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA123a Kings Road | London SW3 4PLTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAURRRRARUBUAR
Date   Source Headline
18th Feb 202210:06 amRNSNet Asset Value(s)
17th Feb 20229:58 amRNSNet Asset Value(s)
16th Feb 20225:31 pmRNSPortfolio Update
16th Feb 20224:39 pmRNSHolding(s) in Company
16th Feb 202210:29 amRNSNet Asset Value(s)
15th Feb 202210:34 amRNSNet Asset Value(s)
14th Feb 202210:26 amRNSNet Asset Value(s)
11th Feb 202212:34 pmRNSGM Statement
11th Feb 202211:06 amRNSNet Asset Value(s)
10th Feb 202210:33 amRNSNet Asset Value(s)
9th Feb 202212:54 pmRNSNet Asset Value(s)
8th Feb 20229:55 amRNSNet Asset Value(s)
7th Feb 202210:56 amRNSNet Asset Value(s)
4th Feb 20225:32 pmRNSDirector/PDMR Shareholding
4th Feb 202211:30 amRNSNet Asset Value(s)
3rd Feb 20224:54 pmRNSFund Manager Share Purchase
3rd Feb 202210:33 amRNSNet Asset Value(s)
2nd Feb 202211:10 amRNSNet Asset Value(s)
1st Feb 20223:25 pmRNSDirector/PDMR Shareholding
1st Feb 20221:53 pmRNSDirector/PDMR Shareholding
1st Feb 20221:31 pmRNSDirector/PDMR Shareholding
1st Feb 202211:04 amRNSNet Asset Value(s)
31st Jan 20226:21 pmRNSTotal Voting Rights
31st Jan 202210:24 amRNSNet Asset Value(s)
28th Jan 202211:50 amRNSAnnual Financial Report
28th Jan 202211:07 amRNSNet Asset Value(s)
27th Jan 202210:50 amRNSNet Asset Value(s)
26th Jan 202210:44 amRNSNet Asset Value(s)
25th Jan 202210:42 amRNSNet Asset Value(s)
24th Jan 202211:05 amRNSNet Asset Value(s)
21st Jan 202211:26 amRNSNet Asset Value(s)
20th Jan 20229:47 amRNSNet Asset Value(s)
19th Jan 20229:33 amRNSNet Asset Value(s)
18th Jan 20224:31 pmRNSPortfolio Update
18th Jan 202210:15 amRNSNet Asset Value(s)
17th Jan 202211:20 amRNSNet Asset Value(s)
14th Jan 202210:06 amRNSNet Asset Value(s)
13th Jan 202210:37 amRNSNet Asset Value(s)
12th Jan 20225:29 pmRNSDirector/PDMR Shareholding
12th Jan 20229:52 amRNSNet Asset Value(s)
11th Jan 202210:28 amRNSNet Asset Value(s)
10th Jan 202210:29 amRNSNet Asset Value(s)
10th Jan 20227:00 amRNSCompany Update
7th Jan 202210:19 amRNSNet Asset Value(s)
6th Jan 202210:29 amRNSNet Asset Value(s)
5th Jan 202210:01 amRNSNet Asset Value(s)
4th Jan 202210:11 amRNSNet Asset Value(s)
31st Dec 202112:53 pmRNSTotal Voting Rights
31st Dec 202110:31 amRNSNet Asset Value(s)
30th Dec 202111:27 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.